<p>Parkinson’s disease is a progressively debilitating neurodegenerative disorder marked by the loss of dopaminergic neurons, with chronic neuroinflammation and oxidative stress playing pivotal roles in its pathogenesis. While current therapeutic regimens provide only symptomatic relief without halting disease progression, attention is shifting toward multi-targeted, disease-modifying strategies. Asperuloside (ASP), a naturally occurring iridoid glycoside derived from medicinal plants, has emerged as a promising neuroprotective candidate with multi-modal therapeutic potential. It exhibits potent anti-inflammatory, antioxidant, and autophagy-enhancing properties by modulating key signaling pathways such as Notch, PI3K/Akt/mTOR, and NF-κB. ASP exerts neuroprotective effects by attenuating glial cell activation, suppressing pro-inflammatory cytokines, restoring mitochondrial function, and promoting neuronal survival. Notably, it facilitates the autophagic clearance of toxic protein aggregates, restores redox balance, and enhances synaptic plasticity and neurogenic signaling. Its regulatory impact on Notch signaling is particularly significant in reprogramming glial phenotypes and fostering neurogenesis. Moreover, ASP's oral bioavailability and potential for brain-targeted delivery position it as a strong translational candidate. Its ability to influence epigenetic regulation, promote selective autophagy (e.g., mitophagy), and synergize with existing pharmacotherapies warrants further investigation. Collectively, ASP represents a next-generation, multi-target neurotherapeutic capable of modulating the intricate network of degenerative pathways in Parkinson’s disease.</p>